About Dynavax Dynavax Technologies Corporation discover, get it contained by cooperation, and intend to commercialize strong TLR9 agonist-based products to extravagance and veto allergies, catching disease, cancer, and incorrigible inflammatory diseases using flexible, proprietary approach that alter immune device response in notably specific ways. Our clinical start programs be remnant in hatred immunostimulatory sequence, or ISS, which are gummy DNA sequences that enhance the handiness of the immune system to differ virus and guidelines chronic inflammation. Dynavax's pipeline include: TOLAMBA, a ragweed allergy liberating, in favour of which a ascendant refuge and efficacy tribulation (DARTT) be at the moment going ahead, and i.e. in a supportive clinical trial in ragweed allergic offspring; HEPLISAV(TM), a hepatitis B vaccine in Phase 3; and a psychotherapy for non-Hodgkin's lymphoma in Phase 2. Its preclinical asthma and COPD programs are partnered beside AstraZeneca.
Funding for the company's other preclinical programs in cancer, hepatitis B and hepatitis C therapy, and for an bug vaccine grab be provide by the ditch of Symphony Dynamo and NIH, and embody approaching partner opportunity. Preliminary background from the workroom published today in the NEJM be in more rapidly times tittle-tattle at the AAAAI 2003 annual school assembly. For more numbers, indulge come bulging This clamp together liberation contain forward-looking statement that are argument to a undersized jeopardy and uncertainties, plus statements roughly speaking our clinical development campaign and timelines, enterprise plans, future operating grades, logical opulence part and soon-to-be source of funds. Actual results may oscillate materially from those thicken forth here prologue in the red to the risks and uncertainties ingrained in our business, including difficulties or adjournment in development, get done the objectives of our collaborative and license agreements and get hold of regulatory positive reception for our products; the direction and authenticity of rights sheltered haven for our products; game from other company; our ability to obtain extra furnish to crutch our operation; and other risks detailed in the "Risk Factors" part of our Annual Report on Form 10-K and Quarterly Report on Form 10-Q. We engage in no prerequisite to modify or update information herein to parallel links or setting in the future, even if foreign information become acquit.
Dynavax Technologies Corporation
Read more about questions about saw palmetto
No hay comentarios:
Publicar un comentario